XENE — Xenon Pharmaceuticals Inc. stock price, charts and financials

QT41Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Inc. (NASDAQ: XENE) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
39.75
-17.60-30.69%
OverviewShort InterestFilings
XENEQT41Xenon Pharmaceuticals Inc.·NASDAQ
39.75-30.69%
News
Down 30.7% — Xenon paused new enrollment in depression and bipolar disorder trials due to side-effect concerns, raising regulatory and commercial risks.
High confidence
TA
Loading chart...
Signal & projected range
Gap down — mean-reversionHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
CPRX+0.00%$31.49ABCL-0.79%$12.63CELC-5.06%$80.61IDYA-0.52%$38.41AMLX-4.51%$32.41RLAY-1.82%$18.84TNGX-7.41%$21.75ELVN-1.57%$49.45
Snapshot
Index-P/E-EPS (ttm)-1.90Insider Own2.56%Shs Outstand96.67MPerf Week-32.23%
Market Cap3.84BForward P/E-EPS next Y-4.74Insider Trans-0.79%Shs Float90.76MPerf Month-36.22%
Enterprise Value3.73BPEG0.31EPS next Q-1.17Inst Own-Short Float6.99%Perf Quarter-24.87%
Income-396.93MP/S0.00EPS this Y-142.59%Inst Trans-Short Ratio5.20Perf Half Y-27.95%
Sales22.00MP/B3.19EPS next Y-2.90%ROA-31.58%Short Interest6.34MPerf YTD-11.31%
Book/sh-P/C-EPS next 5Y-ROE-43.98%52W High72.66 -45.29%Perf Year8.31%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-35.10%52W Low35.97 10.51%Perf 3Y7.55%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-3.85% -24.21%Gross Margin0.00%Volatility4.21% 3.40%Perf 5Y127.79%
Dividend TTM-EV/Sales0.00EPS Y/Y TTM36.88%Oper. Margin0.00%ATR (14)3.02Perf 10Y407.02%
Dividend Ex-Date-Quick Ratio21.02Sales Y/Y TTM-Profit Margin0.00%RSI (14)13.87Recom2.00
Dividend Gr. 3/5Y-Current Ratio21.02EPS Q/Q-3.74%SMA20-32.18%Beta0.60Target Price65.57
Payout0.00%Debt/Eq0.01Sales Q/Q-SMA50-36.20%Rel Volume13.28Prev Close57.35
Employees364LT Debt/Eq0.01EarningsNov 02SMA200-25.57%Avg Volume1.35MPrice39.75
IPO DateNov 05, 2014Option/ShortYes / YesEPS/Sales Surpr.2.76% -Net Debt/EBITDA0.27Volume17,861,674Change-30.69%
Analyst Ratings
DateActionAnalystRatingTarget
Sep-18-26ReiteratedRobert W. Baird$97 → $90
Sep-18-26ReiteratedWedbushOutperform$42 → $55
Sep-18-26ReiteratedRBC CapitalOutperform$81 → $70
Sep-18-26ReiteratedNeedhamBuy$78 → $60
Sep-18-26DowngradeDeutsche BankBuy → Hold$90 → $46
Sep-18-26ReiteratedWells FargoOverweight$69 → $64
Aug-10-26ReiteratedH.C. WainwrightBuy$53 → $74
Aug-07-26ReiteratedRBC CapitalOutperform$80 → $81
May-10-26ReiteratedWells FargoOverweight$68 → $69
May-08-26ReiteratedNeedhamBuy$78
Latest News· Times ET
Sep-18-26
Sep-18-2608:24AM
Xenon Pharmaceuticals falls 30% after depression trial enrollment pauseproactiveinvestors.com
08:10AM
XENE Files NDA for Epilepsy Drug, Falls on Depression Studies' Setbackzacks.com
07:14AM
Xenon Stock Reaction Is Overblown: Analystbenzinga.com
05:14AM
Stock Futures Mixed After Thursday's Reboundschaeffersresearch.com
04:01AM
Xenon Pharmaceuticals, Steel Dynamics, Nucor And Other Big Stocks Moving Lower In Friday's Pre-Market Sessionbenzinga.com
03:32AM
Xenon Stock Faces Worst Day Since 2017 as Lead Drug Proves a Double-Edged Swordbarrons.com
Sep-17-26
Sep-17-2605:29PM
Xenon Pharmaceuticals Inc. (XENE) Discusses Azetukalner NDA Submission for Focal Seizures and Psychiatry Program Update Transcriptseekingalpha.com
05:00PM
These stocks are moving in today's after hours sessionChartMill
12:38PM
Xenon pauses new enrollment in depression, bipolar disorder trials over side-effect concernsreuters.com
12:01PM
Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Programglobenewswire.com
Sep-10-26
Sep-10-2604:17PM
Biohaven Plummets, A Boon For Rival Xenon, On A Surprise Seizure SetbackYahoo
Sep-04-26
Sep-04-2603:06PM
Xenon (XENE) Heads To Europe With Data That Could Reshape Epilepsy CareYahoo
Sep-03-26
Sep-03-2612:01PM
Xenon to Present at Wells Fargo Healthcare Conferenceglobenewswire.com
Aug-28-26
Aug-28-2612:01PM
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com
Aug-27-26
Aug-27-2610:21AM
Biohaven: Buy Reiterated On Opakalim License Agreement For Epilepsy And MoreSeekingAlpha
Company

Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue2280——————
Cost of Goods Sold Incl. D&A8233——————
Gross Profit-625-3——————
Selling, General and Administrative Excl. Other288069——————
Research and Development82301210——————
Other Operating Expense-82-3-2——————
Operating Income-88-373-279——————
Interest Expense
000——————
Unusual Expense
—————————
Non-Operating Income (Expense)592841——————
Net Income Before Taxes-30-345-238——————
Income Taxes621-4——————
Consolidated Net Income-92-346-234——————
Net Income From Continuing Operations-92-346-234——————
Net Income-92-346-234——————
EPS (Recurring)-1.91-4.36-3.01——————
EPS (Basic, Before Extraordinaries)-1.91-4.36-3.01——————
EPS (Diluted)-1.90-4.36-3.01——————
EBITDA-87-342-236——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio101.18442.60———————
Gross Margin-281.8262.50———————
Operating Margin-400.00-4,662.50———————
Net Margin-418.18-4,325.00———————
Shares Outstanding567978——————
Market Capitalization2,2263,5413,058——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$77.06$63.84$50.63$37.42$24.20● Close Price0.00M4.46M8.92M13.38M17.85MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Svoronos DawnDirectorSep 01 '26Option Exercise8.155,14441,92431,373Sep 03
KENNEY CHRISTOPHER JOHNChief Medical OfficerAug 28 '26Sale60.257,068425,8292Aug 31
GANNON STEVENDirectorAug 11 '26Sale64.0610,000640,5501,870Aug 13
Cannon GillianDirectorJun 05 '26Sale53.141,19063,2371,455Jun 08
PATOU GARYDirectorJun 05 '26Sale53.141,32270,25124,896Jun 08
PATOU GARYDirectorJun 01 '26Option Exercise0.002,645026,218Jun 03
Machado PatrickDirectorJun 01 '26Option Exercise0.002,64502,645Jun 03
Gover Justin D.DirectorJun 01 '26Option Exercise0.002,64502,645Jun 03
GAROFALO ELIZABETH A.DirectorJun 01 '26Option Exercise0.002,64502,645Jun 03
GANNON STEVENDirectorJun 01 '26Option Exercise0.002,645013,286Jun 03
Cannon GillianDirectorJun 01 '26Option Exercise0.002,64502,645Jun 03
Svoronos DawnDirectorJun 01 '26Option Exercise0.002,645027,645Jun 03
GANNON STEVENDirectorMay 12 '26Option Exercise7.383,50025,83010,641May 13
DiFabio AndreaChief Legal OfficerMar 13 '26Sale55.231,34274,1127,301Mar 13
MORTIMER IANPRESIDENT & CEOMar 13 '26Sale55.237,308403,58419,923Mar 13
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.